Organization
Internal Medicine III, Wakayama Medical University, Wakayama, Japan
4 abstracts
Abstract
A phase III study comparing EGFR tyrosine kinase inhibitor (EGFR-TKI) monotherapy and EGFR-TKI with inserted cisplatin (CDDP) plus pemetrexed (PEM) as a first-line treatment in patients (pts) with advanced non-squamous non–small-cell lung cancer (NSqNSCLC) harboring EGFR activating mutation (EGFR-NSqNSCLC): JCOG1404/WJOG8214L, AGAIN study.Org: Department of Pulmonary Medicine and Clinical Immunology, Dokkyo Medical University School of Medicine, Mibu, Japan, Department of Biostatistics and Bioinformatics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, Department of Respiratory Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan, Department of Thoracic Oncology, Saitama Cancer Center, Saitama, Japan, Department of Thoracic Oncology, Aichi Cancer Center, Nagoya, Japan,
Abstract
Subcutaneous amivantamab vs intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Primary results, including overall survival (OS), from the global, phase 3, randomized controlled PALOMA-3 trial.Org: Princess Margaret Cancer Centre, Wakayama Medical University, Wakayama, Japan, Division of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine, Jilin Cancer Hospital, Drug Development Unit, The Royal Marsden Hospital and The Institute of Cancer Research,
Abstract
Comprehensive genomic profiling before the first-line setting versus after the completion of standard of care in patients with previously untreated advanced solid tumors: The prospective FIRST-Dx study.Org: Department of Therapeutic Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, Kyoto University Hospital, Kyoto, Japan, Department of Next-Generation Precision Medicine Development Laboratory, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, The University of Tokyo Hospital, Tokyo, Japan, Tokyo Medical and Dental University, Bunkyo-Ku, Japan,
Abstract
A phase III study comparing EGFR tyrosine kinase inhibitor (EGFR-TKI) monotherapy and EGFR-TKI with inserted cisplatin (CDDP) plus pemetrexed (PEM) as a first-line treatment in patients (pts) with advanced non-squamous non–small-cell lung cancer (NSqNSCLC) harboring EGFR activating mutation (EGFR-NSqNSCLC): JCOG1404/WJOG8214L, AGAIN study.Org: Department of Hematology and Clinical Oncology, Shinshu University School of Medicine, Matsumoto-Shi, Japan, Department of Pulmonary Medicine and Clinical Immunology, Dokkyo Medical University School of Medicine, Mibu, Japan, Department of Thoracic Oncology, Kansai Medical University Hospital, Osaka, Japan, Department of Biostatistics and Bioinformatics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, Department of Pulmonary Medicine, Sendai Kousei Hospital, Sendai, Japan,